U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

                For the quarterly period ended February 28, 2005

[ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

                         For the transition period from

                         Commission File No. 000-50814

                   Med-Zone Biotechnologies Acquisition, Inc.
        (Exact name of small business issuer as specified in its charter)

       Delaware
(State or other jurisdiction of                             (I.R.S. Employer
incorporation or organization)                              Identification No.)

                  28W 38th Street, Suite 8W, New York, NY 10018
                    (Address of Principal Executive Offices)

                                  212-398-2880
                           (Issuer's telephone number)



Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the issuer was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ]

Check whether the registrant has filed all documents and reports required to be
filed by Sections 12, 13, or 15(d) of the Exchange Act subsequent to the
distribution of securities under a plan confirmed by a court. Yes [X] No [ ]

State the number of shares outstanding of each of the issuer's classes of common
equity, as of April 10, 2005: 100,000 shares of common stock.





<PAGE>



                   Med-Zone Biotechnologies Acquisition, Inc.
                          (a development stage company)

                              FINANCIAL STATEMENTS

                                      INDEX


Part I-- FINANCIAL INFORMATION

  Item 1. Financial Statements

  Item 2. Management's Discussion and Analysis of Financial Condition

  Item 3. Control and Procedures

Part II-- OTHER INFORMATION

  Item 1. Legal Proceedings

  Item 2. Changes in Securities

  Item 3. Defaults Upon Senior Securities

  Item 4. Submission of Matters to a Vote of Security Holders

  Item 5. Other Information

  Item 6. Exhibits and Reports on Form 8-K

Signature

<PAGE>

Item 1. Financial Information
-----------------------------

BASIS OF PRESENTATION

The accompanying reviewed financial statements are presented in accordance with
U.S. generally accepted accounting principles for interim financial information
and the instructions to Form 10-QSB and item 310 under subpart A of Regulation
S-B. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements. In the opinion of management, all adjustments (consisting only of
normal occurring accruals) considered necessary in order to make the financial
statements not misleading, have been included. Operating results for the nine
months ended February 28, 2005 and from inception (June 7, 2004) through
February 28, 2004 are not necessarily indicative of results that may be expected
for the year ending May 31, 2005. The financial statements are presented on the
accrual basis.

<PAGE>

                     Med-Zone Biotechnologies Acquisition, Inc.
                             (a development stage company)

                              FINANCIAL STATEMENTS







                              AS OF FEBRUARY 28, 2005




                              Financial Statements
                                Table of Contents


Med-Zone Biotechnologies Acquisition, Inc.
(a development stage company)


FINANCIAL STATEMENTS                                                     Page #


         Balance Sheet                                                        1

         Statement of Operations and Retained Deficit                         2


         Statement of Stockholders Equity                                     3


         Cash Flow Statement                                                  4


         Notes to the Financial Statements                                  5-7



<PAGE>
<TABLE>

                   Med-Zone Biotechnologies Acquisition, Inc.
                          (a development stage company)

                                  BALANCE SHEET
                             As of February 28, 2005


                                     ASSETS

<CAPTION>


CURRENT ASSETS                                                    February 28,2005

<S>                                                                  <C>
Cash                                                                 $      (0)
                                                                     ---------




              TOTAL ASSETS                                           $       0
                                                                     =========

                      LIABILITIES AND STOCKHOLDER'S EQUITY

CURRENT LIABILITIES

Accrued expenses                                                     $  1300.8
                                                                     ---------

                  TOTAL LIABILITIES                                  $  1300.8


STOCKHOLDER'S EQUITY

  Preferred Stock - par value $0.001
    10,000,000 shares authorized;
    None issued and outstanding                                              0

  Common Stock - par value $0.001;
    100,000,000 shares authorized;
    100,000 issued and outstanding                                         100

  Additional paid in capital                                                 0

  Accumulated Deficit                                                  (1300.8)
                                                                     ---------

  Total stockholder's equity                                                (0)
                                                                     ---------


                      TOTAL LIABILITIES AND EQUITY                   $       0
                                                                     =========

</TABLE>



   The accompanying notes are an integral part of these financial statements.


                                      F-1


<PAGE>
<TABLE>

                   Med-Zone Biotechnologies Acquisition, Inc.
                          (a development stage company)

                             STATEMENT OF OPERATIONS
            For the Quarter ended February, 2005, and from inception
                  (October 12, 2004) through February 28, 2005

<CAPTION>

                                                          Quarter             From Inception to
                                                    February 28, 2005         February 28, 2005


<S>                                                       <C>                     <C>
REVENUE       Sales                                       $       0               $        0
              Cost of sales                                       0                        0
                                                          ---------                ---------

     GROSS PROFIT                                                 0                        0

     GENERAL & ADMINISTRATIVE EXPENSES                       1300.8                   1300.8
                                                          ---------                ---------

     NET LOSS                                               (1300.8)                 (1300.8)

     ACCUMULATED DEFICIT, BEGINNING BALANCE                       0                        0
                                                          ---------                ---------

     ACCUMULATED DEFICIT, ENDING BALANCE
                                                          $ (1300.8)              $  (1300.8)
                                                          =========                =========


NET EARNINGS PER SHARE

         Basic and Diluted
         Net loss per share                          (Less than .01)

Basic and Diluted Weighted Average
    Number of Common Shares Outstanding                     100,000


</TABLE>




   The accompanying notes are an integral part of these financial statements.


                                      F-2
<PAGE>

<TABLE>

                   Med-Zone Biotechnologies Acquisition, Inc.
                          (a development stage company)

                        STATEMENT OF STOCKHOLDER'S EQUITY
          From inception (October 12, 2004) through February 28, 2005


<CAPTION>

                                      SHARES                COMMON STOCK       ACCUMULATED DEFICIT        TOTAL
                                      ------                ------------       -------------------        -----
<S>                                  <C>                       <C>               <C>                    <C>
Stock issued on acceptance
   Of incorporation expenses
   October 12, 2004                  100,000                   $    100          $           0          $    100

Net loss                                                                               (1300.8)          (1300.8)
                                    --------                   --------          -------------          --------

Total at February 28, 2005           100,000                   $    100          $     (1300.8)         $(1300.8)
                                    ========                   ========          =============          ========

</TABLE>






   The accompanying notes are an integral part of these financial statements.

                                      F-3

<PAGE>
<TABLE>

                   Med-Zone Biotechnologies Acquisition, Inc.
                          (a development stage company)

                             STATEMENT OF CASH FLOWS
                  For the Quarter ended February 28, 2005, and
           from inception (October 12, 2004) through February 28, 2005

<CAPTION>

                                                                                From
CASH FLOWS FROM OPERATING ACTIVITIES                February 28, 2005      Inception

<S>                                                     <C>                 <C>
       Net income (loss)                                $ (1300.8)          $(1300.8)
       Compensation in the form of stock                $       0           $      0
       Increases (Decrease) in accrued expenses            1300.8             1300.8
                                                        ---------           --------

NET CASH PROVIDED OR (USED) IN OPERATIONS                       0                  0

CASH FLOWS FROM INVESTING ACTIVITIES

        None                                                    0                  0

CASH FLOWS FROM FINANCING ACTIVITIES

        None                                                    0                  0

CASH RECONCILIATION

        Net increase (decrease) in cash                         0                  0
        Beginning cash balance                                  0                  0
                                                        ---------           --------

CASH BALANCE AT END OF PERIOD                           $       0           $      0
                                                        =========           ========

</TABLE>



   The accompanying notes are an integral part of these financial statements.



                                      F-4

<PAGE>

                   Med-Zone Biotechnologies Acquisition, Inc.
                          NOTES TO FINANCIAL STATEMENTS

1.   Summary of significant accounting policies:
     ------------------------------------------

Industry - Med-Zone Biotechnologies Acquisition, Inc. (the Company), a Company
incorporated in the state of Delaware as of June 7, 2004, plans to locate and
negotiate with a business entity for the combination of that target company with
The Company. The combination will normally take the form of a merger,
stock-for-stock exchange or stock- for-assets exchange. In most instances the
target company will wish to structure the business combination to be within the
definition of a tax-free reorganization under Section 351 or Section 368 of the
Internal Revenue Code of 1986, as amended. No assurances can be given that The
Company will be successful in locating or negotiating with any target company.

The Company has been formed to provide a method for a foreign or domestic
private company to become a reporting ("public") company whose securities are
qualified for trading in the United States secondary market.

The Company has adopted its fiscal year end to be May 31.

Results of Operations and Ongoing Entity - The Company is considered to be an
ongoing entity. The Company's shareholders fund any shortfalls in The Company's
cash flow on a day to day basis during the time period that The Company is in
the development stage.

Liquidity and Capital Resources - In addition to the stockholder funding capital
shortfalls; The Company anticipates interested investors that intend to fund the
Company's growth once a business is located.

Cash and Cash Equivalents - The Company considers cash on hand and amounts on
deposit with financial institutions which have original maturities of three
months or less to be cash and cash equivalents.

Basis of Accounting - The Company's financial statements are prepared in
accordance with generally accepted accounting principles.

Income Taxes - The Company utilizes the asset and liability method to measure
and record deferred income tax assets and liabilities. Deferred tax assets and
liabilities reflect the future income tax effects of temporary differences
between the financial statement carrying amounts of existing assets and
liabilities and their respective tax bases and are measured using enacted tax
rates that apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. Deferred tax assets are
reduced by a valuation allowance when in the opinion of management, it is more
likely than not that some portion or all of the deferred tax assets will not be
realized. At this time, The Company has set up an allowance for deferred taxes
as there is no company history to indicate the usage of deferred tax assets and
liabilities.

                                       F-5
<PAGE>

Fair Value of Financial Instruments - The Company's financial instruments may
include cash and cash equivalents, short-term investments, accounts receivable,
accounts payable and liabilities to banks and shareholders. The carrying amount
of long-term debt to banks approximates fair value based on interest rates that
are currently available to The Company for issuance of debt with similar terms
and remaining maturities. The carrying amounts of other financial instruments
approximate their fair value because of short-term maturities.

Concentrations of Credit Risk - Financial instruments which potentially expose
The Company to concentrations of credit risk consist principally of operating
demand deposit accounts. The Company's policy is to place its operating demand
deposit accounts with high credit quality financial institutions. At this time
The Company has no deposits that are at risk.

2.   Related Party Transactions and Going Concern:
     --------------------------------------------

The Company's financial statements have been presented on the basis that it is a
going concern in the development stage, which contemplates the realization of
assets and the satisfaction of liabilities in the normal course of business. At
this time The Company has not identified the business that it wishes to engage
in.

The Company's shareholders fund The Company's activities while The Company takes
steps to locate and negotiate with a business entity for combination; however,
there can be no assurance these activities will be successful.

3.   Accounts Receivable and Customer Deposits:
     -----------------------------------------

Accounts receivable and Customer deposits do not exist at this time and
therefore have no allowances accounted for or disclosures made.

4.   Use of Estimates:
     ----------------

Management uses estimates and assumptions in preparing these financial
statements in accordance with generally accepted accounting principles. Those
estimates and assumptions affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities, and the reported revenue
and expenses. Management has no reason to make estimates at this time.

5.   Revenue and Cost Recognition:
     ----------------------------

The Company uses the accrual basis of accounting in accordance with generally
accepted accounting principles for financial statement reporting.

6.   Accrued Expenses:
     ----------------

Accrued expenses consist of accrued legal, accounting and office costs during
this stage of the business.

                                       F-6

<PAGE>

7.   Operating Lease Agreements:
     --------------------------

The Company has no agreements at this time.

8.   Stockholder's Equity:
     --------------------

PREFERRED STOCK includes 10,000,000 shares authorized at a par value of $0.001,
of which no share have issued.

COMMON STOCK includes 100,000,000 shares authorized at a par value of $0.001, of
which 100,000 have been issued for the amount of $100 on June 7, 2004 in
acceptance of the incorporation expenses for the Company.

9.   Required Cash Flow Disclosure for Interest and Taxes Paid:
     ---------------------------------------------------------

The company has paid no amounts for federal income taxes and interest. The
Company issued 100,000 common shares of stock to its sole shareholder in
acceptance of the incorporation expenses for the Company.

10.  Earnings Per Share:
     ------------------

Basic earnings per share ("EPS") is computed by dividing earnings available to
common shareholders by the weighted-average number of common shares outstanding
for the period as required by the Financial Accounting Standards Board (FASB)
under Statement of Financial Accounting Standards (SFAS) No. 128, "Earnings per
Shares". Diluted EPS reflects the potential dilution of securities that could
share in the earnings.


<PAGE>

Item 2. Management's Discussion and Analysis of Financial Conditions and
        Results of Operations
------------------------------------------------------------------------

Plan of Operation
-----------------

The Registrant is continuing its efforts to locate a merger candidate for the
purpose of a merger. It is possible that the registrant will be successful in
locating such a merger candidate and closing such merger. However, if the
registrant cannot effect a non-cash acquisition, the registrant may have to
raise funds from a private offering of its securities under Rule 506 of
Regulation D. There is no assurance the registrant would obtain any such equity
funding.

Results of Operation
--------------------

The Company did not have any operating income from inception (October 12, 2004)
through February 28, 2005. For the quarter ended February, 2005, the registrant
recognized a net loss of $1,118.40. Some general and administrative expenses
during the year were accrued. Expenses for the quarter were comprised of costs
mainly associated with legal and accounting fees.

Liquidity and Capital Resources
-------------------------------

At February 28, 2005 the Company had no capital resources and will rely upon the
issuance of common stock and additional capital contributions from shareholders
to fund administrative expenses pending acquisition of an operating company.

                                      F-7

<PAGE>

Item 3. Controls and Procedures
-------------------------------

(a) Evaluation of disclosure controls and procedures.

Our Chief Executive Officer and Chief Financial Officer (collectively the
"Certifying Officers") maintain a system of disclosure controls and procedures
that is designed to provide reasonable assurance that information, which is
required to be disclosed, is accumulated and communicated to management timely.
Under the supervision and with the participation of management, the Certifying
Officers evaluated the effectiveness of the design and operation of our
disclosure controls and procedures (as defined in Rule [13a-14(c)/15d-14(c)]
under the Exchange Act) within 90 days prior to the filing date of this report.
Based upon that evaluation, the Certifying Officers concluded that our
disclosure controls and procedures are effective in timely alerting them to
material information relative to our company required to be disclosed in our
periodic filings with the SEC.

(b) Changes in internal controls.

Our Certifying Officer has indicated that there were no significant changes in
our internal controls or other factors that could significantly affect such
controls subsequent to the date of his evaluation, and there were no such
control actions with regard to significant deficiencies and material weaknesses.


<PAGE>

                           PART II - OTHER INFORMATION



Item 1.   Legal Proceedings.

          The Company is currently not a party to any pending legal proceedings
          and no such action by, or to the best of its knowledge, against the
          Company has been threatened.

Item 2.   Changes in Securities.

          None

Item 3.   Defaults Upon Senior Securities.

          None

Item 4.   Submission of Matters to a Vote of Security
          Holders.

          No matter was submitted during the quarter ending February 28, 2005,
          covered by this report to a vote of the Company's shareholders,
          through the solicitation of proxies or otherwise.

Item 5.   Other Information.

          None

Item 6.   Exhibits and Reports of Form 8-K.

          (a)  Exhibits

          31.1 Certification pursuant to Section 302 of Sarbanes Oxley Act
               of 2002

          32.1 Certification pursuant to Section 906 of Sarbanes Oxley Act
               of 2002

          (b) Reports of Form 8-K

              On November 12, 2004, we filed an 8K with the SEC based on a
              change in control.

                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, there unto
duly authorized.

                                 Med-Zone Biotechnologies Acquisition, Inc.
                                 Registrant


Date: April 8, 2005              By: /s/ Dennis Chen
                                 -----------------------------------
                                 Dennis Chen
                                 President